LADX LadRx
- 1.967500
- +0.467500+31.17%
LadRx News
LadRx LADX +236% 505(b)(2) Process; Keros KROS -73% Voluntary Halt
LadRx Planning NDA Submission Under 505(b)(2) for Aldoxorubicin and Other Updates
LadRx | 10-Q: Q3 2024 Earnings Report
LadRx: Q2 Earnings Snapshot
LadRx | 10-Q: Q2 2024 Earnings Report
ImmunityBio, LadRx End Licensing Deal for Cancer Drug
Express News | Ladrx and Immunitybio mutually agree to terminate the Aldoxorubicin license.
Express News | Ladrx and Immunitybio Mutually Agree to Terminate Aldoxorubicin License
LadRx | 10-Q: Q1 2024 Earnings Report
Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review
Xoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomol
LadRx Issues 2024 Update to Shareholders
XOMA Acquires Drug Rights From LadRx for $5M
XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million With XOMA Corporation
LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX
LadRx To Carry Out 1-for-100 Reverse Stock Split On May 18th, 2023
May 11th - $LadRx(LADX.US)$ is about to implement a 1-for-100 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from May 18th, 2023.$LadRx(LADX.US)$ slipped 5.74%
LadRx Announces Reverse Stock Split >LADX
LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com
No Data
